Tavares Valéria, Neto Beatriz Vieira, Vilas-Boas Maria Isabel, Pereira Deolinda, Medeiros Rui
Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP) / Pathology and Laboratory Medicine Dep., Clinical Pathology SV/ RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal; ICBAS, Abel Salazar Institute for the Biomedical Sciences, 4050-313 Porto, Portugal; FMUP, Faculty of Medicine, University of Porto, 4200-072 Porto, Portugal.
Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP) / Pathology and Laboratory Medicine Dep., Clinical Pathology SV/ RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal; FMUP, Faculty of Medicine, University of Porto, 4200-072 Porto, Portugal.
Biochim Biophys Acta Rev Cancer. 2022 Sep;1877(5):188778. doi: 10.1016/j.bbcan.2022.188778. Epub 2022 Aug 10.
Venous thromboembolism (VTE) is a cardiovascular disorder frequently diagnosed among cancer patients. Aside from being common, VTE severely deteriorates the prognosis of these patients as they face a higher risk of morbidity and mortality, which makes clinical tools able to identify the patients more prompt to thrombogenesis very attractive. Over the years, several genetic polymorphisms have been linked with VTE susceptibility in the general population. However, their clinical usefulness as predictive biomarkers for cancer-related VTE is yet unclear. Furthermore, as a two-way association between cancer and VTE is well-recognized, with haemostatic components fuelling tumour progression, haemostatic gene polymorphisms constitute potential cancer predictive and/or prognostic biomarkers as well. Thus, in this article, we review the existing evidence on the role of these polymorphisms on cancer-related VTE and their impact on cancer onset and progression. Despite the promising findings, the existing studies had inconsistent results most likely due to their limited statistical power and population heterogeneity. Future studies are therefore required to clarify the role of these polymorphisms in setting of malignancy.
静脉血栓栓塞症（VTE）是一种在癌症患者中经常被诊断出的心血管疾病。VTE不仅常见，还会严重恶化这些患者的预后，因为他们面临更高的发病和死亡风险，这使得能够更迅速地识别血栓形成倾向患者的临床工具非常有吸引力。多年来，几种基因多态性与普通人群的VTE易感性有关。然而，它们作为癌症相关VTE预测生物标志物的临床实用性尚不清楚。此外，由于癌症与VTE之间的双向关联已得到充分认识，即止血成分会促进肿瘤进展，止血基因多态性也构成了潜在的癌症预测和/或预后生物标志物。因此，在本文中，我们回顾了关于这些多态性在癌症相关VTE中的作用及其对癌症发生和进展影响的现有证据。尽管有一些有前景的发现，但现有研究结果不一致，很可能是由于其统计能力有限和人群异质性。因此，需要未来的研究来阐明这些多态性在恶性肿瘤背景下的作用。
